This is Anne Wagstaff's Typepad Profile.
Join Typepad and start following Anne Wagstaff's activity
Join Now!
Already a member? Sign In
Anne Wagstaff
Recent Activity
More than 2 months after the October 1, 2011 deadline, the Centers for Medicare and Medicaid Services (CMS) has finally released the proposed rule that would implement the “Transparency Reports and Reporting of Physician Ownership or Investment Interests” section of the Patient Protection and Affordable Care Act (often referred to... Continue reading
Posted Dec 15, 2011 at Pharmaspective
In what appears to be a complete about-face, earlier this month, the OIG informed Forest’s Chairman, CEO and President, Howard Solomon, that it has decided not to seek his exclusion from federal healthcare programs. This decision stands in stark contrast to the OIG’s initial notification to Solomon of his potential... Continue reading
Posted Aug 30, 2011 at Pharmaspective
The introduction of Vermont’s Data Mining Law and the subsequent court battle and rulings may have accidentally encouraged focused pharmaceutical detailing, the exact practice Vermont sought to squash. In June 2007 the Vermont legislature passed its Prescription Confidentiality Law. According to its text, the Vermont legislature believed that prohibiting the... Continue reading
Posted Jul 1, 2011 at Pharmaspective
On Thursday, June 16, the Vermont Office of the Attorney General held a conference call to discuss its 2011 Draft Consolidated Guide and the revised 2011 reporting forms. Like many of Vermont’s marketing disclosure conference calls, the call focused on the finer details of Vermont’s reporting requirements. One interesting take... Continue reading
Posted Jun 22, 2011 at Pharmaspective
Yesterday marked yet another peculiar move by the OIG in the Solomon saga. Following on the heels of its decision to potentially exclude Howard Solomon from federal healthcare programs, the OIG released on its website the “OIG Fact Sheet on Forest Laboratories, Inc., and the Inspector General's Exclusion Authorities.” The... Continue reading
Posted May 12, 2011 at Pharmaspective
Many articles focus solely on the new features of the most recent government settlement. An April 5, 2011 article entitled, "Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower Complaints", however, sheds light on exactly what kind of alleged off-label practices by pharmaceutical companies resulted in... Continue reading
Posted May 9, 2011 at Pharmaspective
Howard Solomon, the CEO of Forest Laboratories (“Forest”), may be one of the most polarizing figures in the pharmaceutical industry today. Recognized as the driving force behind Forest’s success story, he is seen by many as visionary leader. In the course of seeking an appropriate medication for his mentally ill... Continue reading
Posted May 6, 2011 at Pharmaspective
Anne Wagstaff is now following The Typepad Team
Apr 27, 2011